Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Now Is The Time! Rule Changes To Smooth China New Drug Approvals?

Executive Summary

The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to quicken the pace of launches to potentially overcome China’s “drug lag” and that may also bolster multinationals’ interest and activity in the country.

You may also be interested in...



China FDA Proposes Sweeping Reforms To Incentivize Innovation

The China FDA releases a raft of new regulatory proposals outlining fundamental changes in areas including patent linkage and data exclusivity, which look set to profoundly impact decision makers looking at bringing new drugs and devices to the world’s second-largest pharma market.

Big Pharma CEOs Descend On China: What’s The Likely Agenda?

In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.

Foreign Drugs Welcome As China Reforms Progress: CFDA Commissioner

China’s drug regulators have had plenty of views to offer at recent major government congress sessions in Beijing, which provide a forum for the industry to meet officials and opportunities to outline reform progress and planned policies.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel